Hormone-responsive rat and human mammary tumor, unlike normal epithelium, actively sulfoconjugates estrogens. The title compounds (9-11) were synthesized in search of specific inhibitors of estrogen sulfotransferase as a possible means of developing effective chemotherapeutic agents for treatment of hormone-dependent human mammary cancer. 4-Nitroestrone 3-triflate (7a) was converted to the corresponding estradiol derivative (8a) in 93% yield by reduction with NaBH4 under phase-transfer conditions. Catalytic reduction (10% Pd/C) of the latter gave 4-aminoestra-1,3,5(10)-trien-17 beta-ol (9a) in 77% yield. These same reactions were applied consecutively to 4-nitroestrone 3-nonaflate (7b) to give 9a in 56% overall yield. The amino steroid (9a) was converted to 4-fluoroestra-1,3,5(10)-trien-17 beta-ol (10a) via a Balz-Schiemann reaction, in 17% overall yield. Successive NaBH4 and (10% Pd/C) catalytic reductions of 4-fluoroestrone 3-O-(1-phenyl-1H-tetrazol-5-yl) ether (2b) provided a less satisfactory route to 10a. MCPBA oxidation of 9a gave 4-nitroestra-1,3,5(10)-trien-17 beta-ol (11a) in 56% yield. The same series of reactions were applied to 2-nitroestrone 3-triflate (7c) to give 2-amino- (9b), 2-fluoro- (10b), and 2-nitro- (11b) estra-1,3,5(10)-trien-17-ols in comparable yields. Substitution in the A ring results in improved inhibition of porcine endometrial sulfotransferase sulfoconjugation of estradiol relative to estra-1,3,5(10)-trien-17 beta-ol (4a). Moreover, electronegative substitution at C-4 of 4a is more effective than at C-2. In particular, the Ki (2.43 +/- 0.16 microM) of 11a is sixfold smaller than that of the unsubstituted steroid (4a).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.